- metrii, 6. zvážit možná další onemocnění, která se projeví postižením jícnu (ezofagitidu polékovou, infekční, při onemocnění kůže atd).
Na závěr je nutno vyslovit upozornění, že refrakterní refluxní symptomy, zejména při normálním endoskopickém nálezu, jsou závažným diagnostickým problémem a vyžadují řádné vyšetření!
S podporou MZČR-RVO VFN 64165.
Prohlášení: autor v souvislosti s tématem práce v posledních 12 měsících nespolupracoval s žádnou farmaceutickou firmou..
Literatura
1. HONGO, M. Minimal changes in reflux esophagitis, red ones and white ones. J Gastroenterol, 2006, 41, p. 95–99.
2. SUGIMOTO, M., NISHINO, M., KODAIRA, C., et al. Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy. World J Gastroenterol, 2011, 17, p. 1858–1865.
3. The Montreal Definition and Classification of Gastroesophageal Reflux Disease. A Global Evidence-Based Consensus. Amer J Gastroenterol, 2006, 101, p. 1900–1920. 4. RICHTER, JE. The patient with refractory gastroesophageal reflux disease. Dis Esoph, 2006, 19, p. 443–447.
5. RICHTER, JE. How to manage refractory RCHJ. Nat Clin Pract Gastroenterol Hepatol, 2007, 4, p. 658–664. 6. FORNARI, F., SIFRIM, D. Diagnostic options for patients with refractory RCHJ. Curr Gastroenterol Rep, 2008,10, p. 283–288 .
7. BECKER, V., BAJBOUJ, M., WALLER, K., et al. Clinical trial, persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors – a follow-up study of intraluminal-impedance guided therapy. Aliment Pharmacol Ther, 2007, 26, p. 1355–1360.
8. BREDENROOD, AJ., DENT, J. Proton pump inhibitor-therapy refractory gastroesophageal reflux disease patients, who are they? Gut, 2007, 56, p. 593–600.
9. TYTGAT, GNJ. Esophagology 2008, any progress? Curr Opin Gastroenterol, 2008, 24, p. 482–484.
10. FASS, R., GASIOROWSKA, A. Refractory RCHJ, what is it? Curr Gastroenterol Rep, 2008, 10, p. 252–257.
11. SCARPIGNATO, C. Poor effectiveness of proton pump inhibitors in non-erosive reflux disease, the truth in the end! Neurogastroenterol Motil, 2012, 24, p. 697–704. 12. BARDHAM, KD. The role of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther, 1995, 9(Suppl 1), p. 15–25.
13. GUNARATNAM, NT., JESSUP, TP., INADOMI, J., LASCEWSKI, DP. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther, 2006, 23, p. 1473–1477.
14. HERSHCOVICI, T., FASS, R. An algorithm for diagnosis and treatment of refractory RCHJ. Best Pract Res Clin Gastroenterology, 2010, 24, p. 923–936.
15. CHEN, J., XU, J., XU, Y., XIE, X., YI, C., HOU, X. Analysis on the causes for refractory RCHJ. J Huazhong Univ Sci Technolog Med Sci, 2002, 22, p. 47–49.
16. KAHRILAS, PJ., BOECKXSTAENS, G. Failure of reflux inhibitors in clinical trials, bad drugs or wrong patients? Gut, 2012, 61, p. 1501–1509.
17. KRZNARIC, Z., LJUBAS KELECIC, D., et al. Pharmaceutical principles of acid inhibitors, unmet needs. Dig Dis, 2011, 29, p. 469–475.
18. TUTUIAN, R., VELA, MF., HILL, EG., et al. Characteristics of symptomatic reflux episodes on Acid suppressive therapy. Am J Gastroenterol, 2008, 103, p. 1090–1096. 19. Van MALENSTEIN, H., FARRÉ, R., SIFRIM, D. Esophageal dilated intercellular spaces (DIS) and nonerosive reflux disease. Am J Gastroenterol, 2008, 103, p. 1021–1028. 20. MANCINI, V., RIBOLSI, M., GENTILE, M., et al. Oesophageal mucosal intercellular space diameter and reflux pattern in childhood erosive and non-erosive reflux disease. Dig Liver Dis, 2012, Sep 10. pii, S1590-8658(12)00290-3.
21. HYUN, JJ., BAK, YT. Clinical significance of hiatal hernia. Gut Liver, 2011, 5, p. 267–277. 22. IWATA, A., IKEDA, K., HIROSE, K., et al. Pre-dinner administration increases the efficacy of proton pump inhibitors on refractory RCHJ symptoms in connective tissue disease patients. Mod Rheumatol, 2013, 23, p. 357–364.
23. BARRISON, AF., JARBOE, LA., WEINBERG, BM., et al. Patterns of proton pump inhibitors in clinical practice. Am J Med, 2001, 111, p. 469–473.
24. SOBRINO-COSSÍO, S., LÓPEZ-ALVARENGA, JC., REMES-TROCHE, JM., et al. Proton pump inhibitors in gastroesophageal reflux disease, „a custom-tailored therapeutic regimen“. Rev Esp Enferm Dig, 2012, 104, p. 367–378.
25. SCARPIGNATO, C. Poor effectiveness of proton pump inhibitors in non-erosive reflux disease, the truth in the end! Neurogastroenterol Motil, 2012, 24, p. 697–704. 26. POHLE, T., DOMSCHKE, W. Results of short- and long-term. Medical treatment of gastroesophageal reflux disease. Langenbeck´s Archives of Surgery, 2004, 385, p. 2435–2443.
27. KATZ, PO. Medical therapy for gastroesophageal reflux disease in 2007. Rev Gastroenterol Disord, 2007, 7, p. 193–203.
28. FASS, R. Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease. Am J Gastroenterol, 2003, 98(Suppl. 3), S2–7.
29. DENT, J. Microscopic esophageal mucosal injury in nonerosive reflux disease. Clin Gastroenterol Hepatol, 2007, 5, p. 4–16.
30. MACKALSKI, BA., ILNYCKYJ, A. Esophageal pH testing in patients refractory to proton pump inhibitor therapy. Can J Gastroenterol, 2008, 22, p. 249–252.
31. PANDOLFINO, JE., RICHTER, JE., OURS, T., et al. Ambulatory esophageal pH monitoring using a wireless system. Am J Gastroenterol, 2003, 98, p. 740–749.
32. KOCH, OO., KAINDLSTORFER, A., ANTONIOU, SA., et al. Subjective and objective data on esophageal manometry and impedance pH monitoring 1 year after endoscopic full-thickness plication for the treatment of RCHJ by using multiple Plicator implants. Gastrointest Endosc, 2013, 77, p. 7–14.
33. HEARD, R., SHARMA, N., ROBERTS, J., et al. Wireless ‚mini‘ multichannel intraluminal impedance-pH, what is the optimal design of a miniature wireless device? Dis Esophagus, 2012, Sep 14. doi, 10.1111/j.1442-2050.2012.01410.x.
34. KOHATA, Y., FUJIWARA, Y., MACHIDA, H., et al. Pathogenesis of proton-pump inhibitor-refractory non-erosive reflux disease according to multichannel intraluminal impedance-pH monitoring. J Gastroenterol Hepatol, 2012, 27(Suppl 3), p. 58–62.
35. TACK, J., BLONDEAU, K. Weakly acidic reflux. Dig Dis, 2009, 27, p. 58–61.
36. PANDOLFINO, JE., GHOSH, SK., RICE, J., et al. Classifying esophageal motility by pressure topography characteristics, a study of 400 patients and 75 controls. Am J Gastroenterol, 2008,103, p. 27–37.
37. KAHRILAS, PJ. Esophageal motor disorders in terms of high-resolution esophageal pressure topography, what has changed? Am J Gastroenterol, 2010, 105, p. 981–987. 38. VAEZI, MF., LACAMERA, RG., RICHTER, JE. Validation studies of Bilitec 2000, an ambulatory duodenogastric reflux monitoring system. Am J Physiol Gastrointest Liver Physiol, 1994, 267, G1050–G1057.
39. KOEK, GH., VOS, R., FLAMEN, P., et al. Oesophageal clearance of acid and bile, a combined radionuclide, pH, and Bilitec study. Gut, 2004, 53, p. 21–26.
40. PACE, F., SANGALETTI, O., PALLOTTA, S., et al. Biliary reflux and non-acid reflux are two distinct phenomena, a comparison between 24-hour multichannel intraesophageal impedance and bilirubin monitoring. Scand J Gastroenterol, 2007, 42, p. 1031–1039.
41. TANIMURA, T., ADACHI, K., FURUTA, K.,et al. Usefulness of catheterless radiotelemetry pH monitoring system to examine the relationship between duodenal acidity and upper gastrointestinal symptoms. J Gastroenterol Hepatol, 2011, 26, p. 98–103. 42. GILLIES, RS., STRATFORD, JM., BOOTH, MI., DEHN, TC. Oesophageal pH monitoring using the Bravo catheter-free radio capsule. Eur J Gastroenterol Hepatol, 2007, 19, p. 57–63.
43. OOMMEN, J., BIRK, G., WALKER, D., BRAND, J. The Bravo pH Capsule Reviewed, An Analysis of the Safety and Performance in 342 Cases. Gastrointestinal Endoscopy, 2006, 63, AB244–AB244.
44. FORNARI, F., SIFRIM, D. Diagnostic options for patients with refractory RCHJ. Curr Gastroenterol Rep, 2008, 10, p. 283–238.
45. KATZ, PO. Use of intragastric pH monitoring in gastroesophageal reflux disease. Gastrointest Endosc Clin N Am, 2005,15, p. 277–287.
46. BLACKSTONE, MO. Endoscopic Interpretations. New York : Raven Press, 1984, pp. 24–33.
47. PARKMAN, HP., COHEN, S. Heartburn, Regurgitation, Odynophagia, Chest Pain, and Dysphagia. In HAUBRICH, SW., SCHAFFNER, F., BERK, JE., (Eds), Bockus Gastroenterology. Philadelphia : W. B. Saunders Comp. 1995, pp. 30–40.
48. HAWKEY, CJ. NSAIDs and aspirin, notorious or famous? Lancet, 2009, 11, 374, p. 93–94.
49. WANI, AM., SHIEKH, AG., HUSSAIN, WM., et al. Fluoxetine-induced pill oesophagitis. BMJ Case Rep, 2011, 2011. pii, bcr0920103333.
50. WILLIAMS, JF., SONTAG, SJ., SCHNELL, T., et al. Non-cardiac chest pain, the long-term natural history and comparison with gastroesophageal reflux disease. Am J Gastroenterol, 2009,104, p. 2145–2152.
51. ABID, S., MUMTAZ, K., JAFRI, W., et al. Pill-induced esophageal injury, endoscopic features and clinical outcomes. Endoscopy, 2005, 37, p. 740–744.
52. GEAGEA, A., CELLIER, C. Scope of drug-induced, infectious and allergic esophageal injury. Curr Opin Gastroenterol, 2008, 24, p. 496–501.
53. DRIES, AM., RICHARDSON, P., CAVAZOS, J., et al. Therapeutic intent of proton pump inhibitor prescription among elderly nonsteroidal anti-inflammatory drug users. Aliment Pharmacol Ther, 2009, 30, p. 652–661.
54. WINSTEAD, NS., BULAT, R. Pill Esophagitis. Curr Treat Options Gastroenterol, 2004, 7, p. 71–76.
55. MOOSIG, F., GROSS, WL. Esophagitis during immunosuppression. Z Rheumatol, 2012, 71, p. 326–327.
56. ŠTORK, J. Lichen planus. Pemphigus vulgaris. Epidermolysis bullosa acquisita. Pemphigoid cicatricans. Lyellův syndrom. In ŠTORK, J. (Ed.), Dermatovenerologie. Praha : Galén Karolinum Praha, 2008, ss. 180–183, 196–200, 205–208.
57. KEATE, RF. Lichen plan,us, report of three patients treated with oral tacrolimus or intraesophageal corticosteroid injection or both. Dis Esophagus, 2003, 16, p. 47–53. 58. MILLER, LS., VINAYEK, R., FRUCHT, H., et al. Reflux esophagitis in patients with the Zollinger-Ellison syndrome. Gastroenterology, 1990, 98, p. 341–346.
59. POITRAS, P., GINGRAS, MH., REHFELD, JF. The Zollinger-Ellison syndrome, dangers and consequences of interrupting antisecretory treatment. Clin Gastroenterol Hepatol, 2012, 10, p. 199–202.
60. METZ, DC. Diagnosis of the Zollinger–Ellison syndrome. Clin Gastroenterol Hepatol, 2012, 10, p. 126–130.
61. FURUTA T, SHIRAI, N., WATANABE, F., et al. Effect of the cytochrome P45O2C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther, 2002, 72, p. 453–460.
62. ZVYAGA, T., CHANG, SY., CHEN, C., et al. Evaluation of Six Proton Pump Inhibitors As Inhibitors of Various Human Cytochromes P450, Focus on Cytochrome P450 2C19. Drug Metab Dispos, 2012, 40, p. 1698–1711.
63. SCHWAB, M., KLOTZ, U., HOFMANN, U., et al. Esomeprazole induced healing of gastroesophageal reflux disease is unrelated to the genotype CYP2C19, Evidence from clinical and pharmacokinetic data. Clin Pharmacol Ther, 2005, 78, p. 627–634. 64. FOX, VL., NURKO, S., FURUTA, GT. Eosinophilic esophagitis, it‘s not just kids stuff. Gastrointest Endosc, 2002, 56, p. 260–270.
65. HAGYMÁSI, K., MÜLLNER, K., HERSZÉNYI, L., TULASSAY, Z. Update on the pharmacogenomics of proton pump inhibitors. Pharmacogenomics, 2011, 12, p. 873–888. 66. SGOUROS, SN., MANTIDES, A. Refractory Heartburn to Proton Pump Inhibitors, Epidemiology, Etiology and Management. Digestion, 2006, 73, p. 218–226.
67. SERRANO, DR., TORRADO, S., TORRADO-SANTIAGO, S., et al. The influence of CYP2C19 genetic polymorphism on the pharmacokinetics/pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatments. Curr Drug Metab, 2012, Apr 10. 22493986.
68. EGAN, LJ., MYHRE, GM., MAYS, DC., et al. CYP2C19 pharmacogenetics int the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease, variant alleles predict gastric acid supression, but no oesophageal acid exposure or reflux symptoms. Aliment Pharmacol Ther, 2003, 17, p. 1521–1528.
69. PASHA, SF., DIBAISE, JK., KIM, HJ., et al. Patient characteristics, clinical, endoscopic, and histologic findings in adult eosinophilic esophagitis, a case series and systematic review of the medical literature. Dis Esophagus, 2007, 20, p. 311–319.
70. MÜLLER, S., PÜHL, S., VIETH, M., STOLTE, M. Analysis of symptoms and endoscopic findings in 117 patients with histological diagnoses of eosinophilic esophagitis. Endoscopy, 2007, 39, p. 339–344.
71. CHEHADE, M., SAMPSON, HA. Epidemiology and etiology of eosinophilic esophagitis. Gastrointest Endosc Clin N Am, 2008, 18, p. 33–44.
72. MORROW, JB., VARGO, II. JJ., GOLDBLUM, JR., et al. The ringed esophagus, histological features of RCHJ. Am J Gastroenterol, 2001, 96, p. 984–989.
73. NGO, P., FURUTA, GT., ANTONIOLI, DA., et al. Eosinophils in the esophagus—peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. Am J Gastroenterol, 2006, 101, p. 1666–1670.
74. STRAUMANN, A. Natural history of primary eosinophilic esophagitis, a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology, 2003, 125, p. 1660–1669. 75. TEITELBAUM, J., FOX, V., TWAROG, F., et al. Eosinophilic esophagitis in children, immunopathological analysis and response to fluticasone propionate. Gastroenterology, 2002, 122, p. 1216–1225.
76. KONIKOFF, M., NOEL, R., BLANCHAR, D., et al. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology, 2006, 131, p. 1381–1391.
77. PEGHINI, P., KATZ, P., CASTELL, D. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole, a controlled study in normal subjects. Gastroenterology, 1998, 115, p. 1335–1339.
78. KRAICHELY, RE., FARRUGIA, G. Achalasia, physiology and ethiopathogenesis. Dis Esoph, 2006,19, p. 213–223.
79. SMOUT, AJPM. Advances in esophageal motor disorders. Curr Opinion Gastroenterol, 2008, 24, p. 485–489.
80. PORTALE, G., COSTANTINI, M., ZANINOTTO, G., et al. Pseudoachalasia, not only esophago-gastric cancer. Dis Esoph, 2007, 20, p. 168–172.
81. KRARUP, AL., LIAO, D., GREGERSEN, H., et al. Nonspecific motility disorders, irritable esophagus, and chest pain. Ann N Y Acad Sci, 2013, 1300, p. 96–109.
82. WONG, RKH., MAYDONOVITCH, CL. Achalasia. In CASTELL, DO. (Ed.), The Esophagus. Philadelphia : Lippincott Williams & Wilkins, 1999, p. 185–213. 83. CAMACHO-LOBATO, L., KATZ, PO., EVELAND, J., et al. Vigorous achalasia, original description requires minor change. J Clin Gastroenterol, 2001, 33, p. 375–377. 84. FACKLER, W., OURS, T., VAEZI, M., RICHTER, J. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology, 2002, 122, p. 625–632. 85. SCARPIGNATO, C., POLOSINI, I. Review artcicle, the opportunities and benefits of extended acid suppresion. Aliment Pharm Ther, 2006, 23(Suppl. 2), p. 23–34.
86. Von RAHDEN, BH., SCHEURLEN, M., FILSER, J., et al. Newly recognized side-effects of proton pump inhibitors. Arguments in favour of fundoplication for RCHJ? Chirurg, 2012, 83, p. 38–44.
87. GARCÍA-ALONSO, FJ., MARTÍN-MATEOS, RM., GONZÁLEZ MARTÍN, JA., et al. Gastric polyps, analysis of endoscopic and histological features in our center. Rev Esp Enferm Dig, 2011, 103, p. 416–420.
88. SIFRIM, D., HOLLOWAY, R., SILNY, J., XIN, Z., et al. Acid, non-acid, and gas reflux in patients with gastro-esophageal reflux disease during ambulatory 24-hour pH-impedance recordings. Gastroenterology, 2001, 120, p. 1588–1598.
89. RACKOFF, A., AGRAWAL, A., HILA, A., et al. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis. Esophagus, 2005, 18, p. 370–373.
90. DROSSMANN, DA. The Functional Gastrointestinal Disorders and the Rome III Process. Gastroenterology, 2006, 130, p. 1377–1390.
91. SAVARINO, E., ZENTILIN, P., MASTRACCI, L., et al. Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn. J Gastroenterol, 2013, 48, p. 473–482.
92. BARLOW, WJ., ORLANDO, RC. The Pathogenesis of Heartburn in Nonerosive Reflux Disease, A Unifying Hypothesis. Gastroenterology, 2005, 128, p. 771–778.
93. De VAULT, KR. Review article, the role of acid supression in patients with non-erosive reflux disease or functional heartburn. Aliment Pharm Ther, 2006, 23(S 1), p. 33–39. 94. ANDERS, A., KOTT, A. Sertralinum. Remedia, 2004, 14, s. 11–17.
95. PEGHINI, P., KATZ, P., CASTELL, D. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole, a controlled study in normal subjects. Gastroenterology, 1998, 15, p. 1335–1339.
96. FACKLER, W., OURST VAEZI, M., RICHTER, K. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology, 2002, 122, p. 625–632. 97. HIRANO, I. Review article, modern technology int the diagnosis of gastroesoophageal reflux disease – Bilitec, intraluminal impedance and Bravo capsule pH monitoring. Aliment Pharm Ther, 2006, 23(Suppl 1), p. 12–24.
98. STRAUMANN, A. Natural history of primary eosinophilic esophagitis, a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology, 2003, 125, p. 1660–1669. 99. GALMICHE, J., CLOUSE, R., BÁLINT, A., et al. Functional esophageal disorder. Gastroenterology, 2006, 130, p. 1459–1465.
100. KIKENDALL, JW. Pill-induced esophageal injury. In CASTELL, DO., RICHTER, JE., (Eds), The Esophagus. Philadelphia : Lippincott Williams and Wilkins 2004, p. 572–584. 101. FURUTA, T., SHIMATANI, T., SUGIMOTO, M., et al. Investigation of pretreatment prediction of proton pump inhibitor (IPP)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of IPPs-TORNADO study, a multicenter prospective study by the Acid-Related Symptom Research Group in Japan. J Gastroenterol, 2011, 46, p. 1273–1283.
102. SHIMATANI, T., SUGIMOTO, M., NISHINO, M., et al. Predicting the efficacy of proton pump inhibitors in patients with non-erosive reflux disease before therapy using dual-channel 24-h esophageal pH monitoring. J Gastroenterol Hepatol, 2012, 27, p. 899–906.
103. KINOSHITA, Y., ASHIDA, K., HONGO, M. Japan Rabeprazole Study Group for NERD. Randomised clinical trial, a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease. Aliment Pharmacol Ther, 2011, 33, p. 213–224.
104. FUTAGAMI, S., IWAKIRI, K., SHINDO, T., KAWAGOE, T., et al. The prokinetic effect of mosapride citrate combined with omeprazole therapy improves clinical symptoms and gastric emptying in IPP-resistant NERD patients with delayed gastric emptying. J Gastroenterol, 2010, 45, p. 413–421.
105. KALTENBACH, T., CROCKETT, S., GERSON, LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med, 2006,166, p. 965–971.
106. MAINIE, I., TUTUIAN, R., CASTELL, DO. Addition of a H2 receptor antagonist to IPP improves acid control and decreases nocturnal acid breakthrough. J Clin Gastroenterol, 2008, 42, p. 676–679.
107. FRAZZONI, M., MANNO, M., DE MICHELI, E., et al. Eficacy in intra-oesophageal acid suppression may decrease after 2-year continuous treatment with proton pump inhibitors. Dig Liver Dis, 2007, 39, p. 415–421.
108. EZZAT, WF., FAWAZ, SA., FATHEY, H., EL DEMERDASH, A. Virtue of adding prokinetics to proton pump inhibitors in the treatment of laryngopharyngeal reflux disease, prospective study. J Otolaryngol Head Neck Surg, 2011, 40, p. 350–356.
109. MOAYYEDI, P., SANTANA, J., KHAN, M., et al. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev, 2011, Feb 16(2),CD003244.
110. ORR, WC., GOODRICH, S., WRIGHT, S., et al. The effect of baclofen on nocturnal gastroesophageal reflux and measures of sleep quality, a randomized, cross-over trial. Neurogastroenterol Motil, 2012, 24, p. 553–559.
111. BOECKXSTAENS, GE., DENISON, H., JENSEN, JM., et al. Translational gastrointestinal pharmacology in the 21st century, ‚the lesogaberan story‘. Curr Opin Pharmacol, 2011, 11, p. 630–633.
112. D‘CUNHA, J., ANDRADE, RS., MADDAUS, MA. Surgical management of gastroesophageal reflux disease/Barrett‘s esophagus. Minerva Chir, 2011, 66, p. 7–19. 113. OELSCHLAGER, BK., MA, KC., SOARES, RV., et al. A broad assessment of clinical outcomes after laparoscopic antireflux surgery. Ann Surg, 2012, 256, p. 87–94. 114. PAGE, MP., KASTENMEIER, A., GOLDBLATT, M., et al. Medically refractory gastroesophageal reflux disease in the obese, what is the best surgical approach? Surg Endosc, 2013, Dec 6. DOI 10.1007/s00464-013-3343-3.
115. LOCKE, GR., 3RD, HORWHAT, J., MASHIMO, H., et al. Endotherapy for and tailored approaches to treating GERD, and refractory GERD. Ann N Y Acad Sci, 2013,1300, p. 166–186.
116. FRANCIOSA, M., TRIADAFILOPOULOS, G., MASHIMO, H. Stretta Radiofrequency Treatment for GERD, A Safe and Effective Modality. Gastroenterol Res Pract, 2013, 2013, p. 783–815.
117. SCHIEFKE, I., ZABEL-LANGHENNIG, A., NEUMANN, S., et al. Long term failure of endoscopic gastroplication (EndoCinch). Gut, 2005, 54, p. 752–758.
118. BELL, RCW., HUFFORD, RJ., FEARON, JF., FREEMAN, KD. Revision of failed traditional fundoplication using EsophyX® transoral fundoplication. Surg Endosc, 2013, 27, p. 761–767.
e-mail: klukas@vfn.cz
O autorovi| MUDr. Karel Lukáš, CSc. Univerzita Karlova v Praze, 1. lékařská fakulta a Všeobecná fakultní nemocnice, IV. interní klinika – klinika gastroenterologie a hepatologie